Diagnostic Imaging Devices are used for the visualization of structural and functional patterns of organs or tissues. A Nuclear Imaging agent is a compound, usually based on a drug molecule, that includes a small amount of radioactive material, or radiotracer. Radiotracers emit a signal that can be detected by a Single Photon Emission Computed Tomography (SPECT) camera or a Positron Emission Tomography (PET) camera. GlobalData uses proprietary data and analytics to provide a comprehensive report on the nuclear imaging agents devices market, including market shares of different players within the UK. Buy the latest report here.
In 2023, GlobalData’s Market Model methodology determined that the leading player in the nuclear imaging agents market in the UK was GE HealthCare Technologies followed by Bracco Diagnostics, Lantheus Medical Imaging, Cardinal Health and Advanced Accelerator Applications.
PET Imaging Agents include Copper-Based PET Imaging Agents, Fluorine-Based PET Imaging Agents, Gallium-68-Based PET Imaging Agents and Rubidium-Based PET Imaging Agents. SPECT Imaging Agents includes Indium-Based SPECT Imaging Agents, Iodine-Based SPECT Imaging Agents, Lutetium-Based SPECT Imaging Agents, Technetium-Based SPECT Imaging Agents and Thallium-Based SPECT Imaging Agents.
The value of the nuclear imaging agents devices market within the UK was expected to be over $20m in 2023.
For the latest complete market share analysis of nuclear imaging agents device market in the UK, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.